<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">In 2013, the AABB TTD emerging infections working group rejected the use of specific screening questions and referenced the FDA guidance on SARS for donors who spontaneously provide a history of exposure or illness [
 <xref ref-type="bibr" rid="CR71">71</xref>]. Were a donor to provide such information during screening, the deferral criteria used for SARS (14 days from the last exposure and 28 days from completion of treatment and resolution of illness) seem rational, if wholly empirical.
</p>
